India Court Rules Natco CL Of Bayer Drug Does Not Extend To Exports
This article was originally published in PharmAsia News
The Delhi High Court ruled the India government's grant of a compulsory license for Natco Pharma to market a generic of Bayer's Nexavar (sorafenib) for treating kidney and liver cancers did not carry a right to export it.
You may also be interested in...
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.
Neuraxpharm has struck a deal to acquire Glenmark’s CNS portfolio in Poland. As part of the agreement, Glenmark’s Jacek Sawicki has been named as general manager of Neuraxpharm Polska and will lead a business that now incorporates Glenmark’s CNS commercial team.
Cardiovascular Sales & Earnings Round-Up: Medtronic TAVR Disappoints While Abbott And Boston Scientific See Structural Success In 2019
The top five cardiovascular device companies, as ranked by Medtech Insight’s MTI 100, have reported their sales and earnings for the last quarter of the calendar year 2019. Here are the highlights from the most recent presentations from Medtronic, Abbott Laboratories, Boston Scientific, Edwards Lifesciences and Terumo.